Breaking the Barrier: TheWell Bioscience Launches VitroGel-Based Cell Invasion Assay Kits to Help Researchers Explore More Types of Migration and Invasion Studies Faster and Easier

TheWell Bioscience, a pioneer of 3D biomimicking platforms for precision medicine, cell therapy, and biomanufacturing, announces the launch of VitroGel®-Based Cell Invasion Assay Kits. Using the xeno-free VitroGel® hydrogels, these new kits revolutionize how researchers study cell migration and invasion, offering unprecedented accuracy, efficiency, and reliability for cell migration assays. The VitroGel-Based Cell Invasion Assay Kits protocol can be completed within 30 minutes compared to hours with an assay kit using an animal-based extracellular matrix (ECM).

The cell migration and invasion assay market is estimated to be worth $1.3 billion. Cell invasion assays empower researchers to understand the vital process in various biological contexts that can be pivotal in embryonic development, immunosurveillance, and wound healing while also playing a concerning role in cancer metastasis for therapeutic developments. Traditionally, in vitro invasion assays have relied on animal-based ECM, which comes with challenges such as undefined components, batch-to-batch variability, and long and cumbersome temperature-sensitive protocols, thus leading to inconsistent and inaccurate studies. In addition, the ECM mechanical strength cannot be manipulated, which obscures the clear understanding of the specific effects of each ECM factor on cell mobility, which is crucial in complete migration and invasion studies.

The VitroGel-Based Cell Invasion Assay Kits solve many of the limitations of animal-based ECM but, most importantly, allow complete control of ECM factors for more accurate and consistent invasion and migration studies. They are powered by VitroGel® hydrogels and the premium quality VitroPrime™ Cell Culture Inserts.

Start with the “ready-to-use” VitroGel® Cell Invasion Assay Kit (which includes our VitroGel® Hydrogel Matrix) for traditional cell invasion assay studies. Go further with any of the “tunable,” high-concentration VitroGel-Based Cell Invasion Assay Kits, where the biophysical and biochemical properties can be manipulated, allowing researchers to explore how different ligands, matrix strengths, chemokines, growth factors, and others that influence cell invasion. In addition, all the VitroGel-Based Cell Invasion Assay Kits can be adapted for laboratory automation for high-throughput assay analysis.

“We were inundated with inquiries to harnessing the power of our xeno-free tunable VitroGel system for cell migration and invasion assay studies,” said John Huang, CEO of TheWell Bioscience. “The new VitroGel-Based Cell Invasion Assay Kits fulfill the need to understand the properties of ECM on cell behaviors and can be leveraged for high-throughput laboratory automation. Researchers can now generate deep insights into how ECM factors influence cell mobility faster, accurately, and consistently. We believe unraveling the intricacies of the microenvironment’s impact on cell invasion and migration will advance therapies for various diseases.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”